Physician profile
Mark S Steadman
NPI 1356309967
$982.60
in general payments reported to CMS, 2019-2025
21 companies · $69.67 in 2025
The $69.67 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $829 · 2020: $30.35 · 2021: $17.48 · 2022: $36.43 · 2025: $69.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $69.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $69.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $150.03 | 2019 | |
| Novartis Pharmaceuticals Corporation | $144.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $125.44 | 2019 | |
| Novo Nordisk INC | $91.63 | 2019-2020 | |
| Avita Medical Americas, LLC | $69.67 | 2025 | Recell, Cohealyx, Permeaderm |
| Astellas Pharma US INC | $59.10 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.38 | 2019 | |
| Amgen INC. | $40.21 | 2019 | |
| Vanda Pharmaceuticals INC. | $35.11 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.72 | 2019 | |
| Janssen Pharmaceuticals, INC | $29.97 | 2019 | |
| Pfizer INC. | $22.22 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.95 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.80 | 2022 | |
| Boston Scientific Corporation | $18.60 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $13.12 | 2019 | |
| Abbott Laboratories | $13.09 | 2019 | |
| Amarin Pharma, INC. | $12.43 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.00 | 2019 | |
| Merck Sharp & Dohme LLC | $11.03 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Steadman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.